Sure, no problems. Take the puritanical hardline in the absolute sense if you want. Your choice. Just don't wonder why ADXS can't compete with other biotechs for the best talent, and if that might cost them somehow progressing the science. For better or worse the reality is that options are a big part of compensation packages in corporate America.
Personally I think it would be much more beneficial for investors to target their wrath over the PPS where it's warranted.
News 
Market Data 
Discover 
